Limitations of using outcomes in the placebo arm of a clinical trial of benign prostatic hyperplasia to quantify those in the community

Mayo Clinic Proceedings

Volumn 80, Issue 6, 2005, Pages 759-764

  Roberts, Rosebud O ^a   Lieber, Michael M ^a   Jacobson, Debra J ^a   Girman, Cynthia J ^a,b   Jacobsen, Steven J ^a  

^a Mayo Clinic   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMMUNITY CARE; COMPARATIVE STUDY; DISEASE COURSE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PROSTATE HYPERTROPHY; QUESTIONNAIRE; RISK ASSESSMENT; UNITED STATES; URINE RETENTION;

EID: 20044366194     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-6196(11)61530-9     Document Type: Article

References (31)

1. Jacobsen SJ, Guess HA, Panser L, et al. A population-based study of health care-seeking behavior for treatment of urinary symptoms: the Olmsted County Study of Urinary Symptoms and Health Status Among Men. Arch Fam Med. 1993;2:729-735.
2. Roberts RO, Rhodes T, Panser LA, et al. Natural history of prostatism: worry and embarrassment from urinary symptoms and health care-seeking behavior. Urology. 1994;43:621-628.
3. Neal DE. Watchful waiting or drug therapy for benign prostatic hyperplasia? Lancet. 1997;350:305-306.
4. Jacobsen SJ, Jacobson DJ, Girman CJ, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol. 1997;158:481-487.
5. Jacobsen SJ, Jacobson DJ, Girman CJ, et al. Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status. J Urol. 1999;162:1301-1306.
6. Thorpe A, Neal D. Benign prostatic hyperplasia [published correction appears in Lancet. 2003;362:496]. Lancet. 2003;361:1359-1367.
7. Temml C, Brossner C, Schatzl G, et al, Prostate Study Group of the Austrian Society of Urology. The natural history of lower urinary tract symptoms over five years. Eur Urol. 2003;43:374-380.
8. Roehrborn CG, McConnell JD, Saltzman B, et al, PLESS Study Group. Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes. Eur Urol. 2002;42:1-6.
9. Kirby RS. The natural history of benign prostatic hyperplasia: what have we learned in the last decade? Urology. 2000;56(5, suppl 1):3-6.
10. Anderson JB, Roehrborn CG, Schalken JA, Emberton M. The progression of benign prostatic hyperplasia: examining the evidence and determining the risk. Eur Urol. 2001;39:390-399.
11. Bautista OM, Kusek JW, Nyberg LM, et al. Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial. Control Clin Trials. 2003;24:224-243.
12. Guess HA, Jacobsen SJ, Girman CJ, et al. The role of community-based longitudinal studies in evaluating treatment effects: example: benign prostatic hyperplasia. Med Care. 1995;33(4, suppl):AS26-AS35.
13. Sech SM, Montoya JD, Bernier PA, et al. The so-called "placebo effect" in benign prostatic hyperplasia treatment trials represents partially a conditional regression to the mean induced by censoring. Urology. 1998;51:242-250.
14. Roehrborn CG. The placebo effect in the treatment of benign prostatic hyperplasia. In: Kirby R, McConnell J, Fitzpatrick J, Roehrborn C, Boyle P, eds. Textbook of Benign Prostatic Hyperplasia. Oxford, England: Isis Medical Media; 1996:239-258.
15. Chute CG, Panser LA, Girman CJ, et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol. 1993;150:85-89.
16. McConnell JD, Roehrborn CG, Bautista OM, et al, Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387-2398.
17. Melton LJ III. History of the Rochester Epidemiology Project. Mayo Clin Proc. 1996;71:266-274.
18. Barry MJ, Fowler FJ Jr, O'Leary MP, et al, Measurement Committee of the American Urological Association. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol. 1992;148:1549-1557.
19. Epstein RS, Deverka PA, Chute CG, et al. Validation of a new quality of life questionnaire for benign prostatic hyperplasia. J Clin Epidemiol. 1992;45:1431-1445.
20. Terris MK, Stamey TA. Determination of prostate volume by transrectal ultrasound. J Urol. 1991;145:984-987.
21. Nickel JC, Canadian PROSPECT Study Group. Placebo therapy of benign prostatic hyperplasia: a 25-month study. Br J Urol. 1998;81:383-387.
22. Lepor H, Williford WO, Barry MJ, et al, Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med. 1996;335:533-539.
23. Lepor H, Laddu A. Terazosin in the treatment of benign prostatic hyperplasia: the United States experience. Br J Urol. 1992;70(suppl 1):2-9.
24. Christensen MM, Bendix Holme J, Rasmussen PC, et al. Doxazosin treatment in patients with prostatic obstruction: a double-blind placebo-controlled study. Scand J Urol Nephrol. 1993;27:39-44.
25. Gormley GJ, Stoner E, Bruskewitz RC, et al, Finasteride Study Group. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med. 1992;327:1185-1191.
26. Finasteride Study Group. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate. 1993;22:291-299.
27. Andersen JT, Ekman P, Wolf H, et al, Scandinavian BPH Study Group. Can finasteride reverse the progress of benign prostatic hyperplasia? a two-year placebo-controlled study. Urology. 1995;46:631-637.
28. McConnell JD, Bruskewitz R, Walsh P, et al, Finasteride Long-Term Efficacy and Safety Study Group. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 1998;338:557-563.
29. Mochtar CA, Kiemeney LA, Laguna MP, et al. Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting. Urology. 2005;65:300-305.
30. Panser LA, Chute CG, Girman CJ, et al. Effect of several recruitment strategies on response rates at baseline in a prospective cohort investigation: the Olmsted County Study of Urinary Symptoms and Health Status among Men. Ann Epidemiol. 1994;4:321-326.
31. Roberts RO, Jacobson DJ, Girman CJ, Rhodes T, Lieber MM, Jacobsen SJ. Prevalence of prostatitis-like symptoms in a community based cohort of older men. J Urol. 2002;168:2467-2471.